Haplomic Technologies nabs EU, US patents
Haplomic Technologies has secured European and US patents covering its key IP, which involves methods for haplotyping the human genome.
Haplotyping involves identifying through DNA sequencing the elements of a haplotype - the basic blocks of genetic material inherited from parents.
Chromosomes are a paired series of contiguous haplotype and the distribution of alleles between haplotype pairs is known as the haplotypic phase.
Current sequencing technologies and advances, including the Human Genome Project, do not take into account the haplotypic phase.
This means that if an individual has two mutations on one gene, current technologies cannot accurately determine if the mutations are present on one chromosome inherited from one parent or the two genes inherited from both parents.
Haplomic Technologies is developing technologies based around haplotyping. The technologies have applications in genomics in the fields of disease risk analysis, pharmacogenomics, personalised medicine and transplantation.
The company was founded in 2003 based on IP from Dr Malcolm Simons, the co-founder of Genetic Technologies (ASX:GTG).
Simons was the first scientist to determine that non-coding DNA regions - so-called ‘junk DNA’ - still play a functional role in genetics.
Mouth bacteria linked to increased head and neck cancer risk
More than a dozen bacterial species that live in people's mouths have been linked to a...
Life expectancy gains are slowing, study finds
Life expectancy at birth in the world's longest-living populations has increased by an...
Towards safer epilepsy treatment for pregnant women
New research conducted in organoids is expected to provide pregnant women with epilepsy safer...
